pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

388 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT776Endpoints580BioPharma Dive223onclive165Fierce Biotech54BioSpace52raps24
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6Hematology
  • <![CDATA[Transformational Utah Investment in Artificial Intelligence and Computing to Advance Health and Discovery]]>
    <![CDATA[The State of Utah has made a visionary investment in AI and advanced computing infrastructure to advance research.]]>
    onclive · 2mo ago↗ source
  • Novo hikes guidance on Wegovy pill’s fast sales start
    <p>In its latest earnings report, the Danish drugmaker said sales and profit should shrink less than the company originally anticipated thanks to strong prescription numbers for its new obesity pil…
    BioPharma Dive · 2mo ago↗ source
  • Avalo shares spike on skin drug data; BioNTech to cut staff
    <figure><div><img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0x…
← prev
page 14 of 16
next →
6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
BioPharma Dive · 2mo ago
↗ source
  • <![CDATA[ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Go]]>
    <![CDATA[Breast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting. ]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Consensus Viewpoints Offer Guidance in Rapidly Evolving Multiple Myeloma Management]]>
    <![CDATA[Ajai Chari, MD, outlines key consensus viewpoints and recommendations for multiple myeloma management from Bridging the Gaps 2025.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Comparing Approved Checkpoint Inhibitor Regimens and Optimal Treatment Duration]]>
    <![CDATA[New SGO 2026 data shows frontline checkpoint inhibitors deliver 4-year survival gains and near-zero relapse after two years in DMMR cancers.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Disease Assessment and Mutational Testing in Progressive CLL]]>
    <![CDATA[Experts discuss relapsed CLL workup, using PET-CT and lymph node biopsy to rule out Richter’s, plus resistance testing to guide next therapy.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Clinical Scenario Presentation and Treatment Approach for Progressive Disease]]>
    <![CDATA[Experts weigh mutation testing, comorbidities, and patient preference to guide second-line CLL options after BTK inhibitor resistance.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Pant on the Mechanism of Action of Daraxonrasib in PDAC]]>
    <![CDATA[Shubham Pant, MD, MBBS, explains the unique "on-state" binding mechanism of daraxonrasib.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Four-Year Follow-Up Outcomes in dMMR Endometrial Cancer Presented at SGO 2026]]>
    <![CDATA[SGO 2026 data shows frontline checkpoint inhibitors in dMMR gynecologic cancer drive flat survival curves, hinting at cure and less chemo.]]>
    onclive · 2mo ago↗ source
  • CellCentric raises $220M for a ‘transformative’ multiple myeloma medicine
    <figure><div><img src="https://imgproxy.divecdn.com/aUhcesS0eCO3NThNNqPfIC_gM2-0lSalzL7WEg-RP7g/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy02ODA4MDQ3ODAuanBn.…
    BioPharma Dive · 2mo ago↗ source
  • <![CDATA[Simlukafusp Alfa Regimens Show Manageable Safety and Activity But Do Not Outperform SOC in Metastatic RCC]]>
    <![CDATA[Simlukafusp alfa plus atezolizumab with/without bevacizumab was safe and active but did not improve upon responses with SOC treatments in metastatic RCC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Cohen on Frontline Chemotherapy Selection in Metastatic Pancreatic Cancer ]]>
    <![CDATA[Deirdre J. Cohen, MD, MS, discusses clinical decision-making and the comparative efficacy of FOLFIRINOX and NALIRIFOX in metastatic pancreatic cancer.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Pant on Managing Toxicities With Daraxonrasib in PDAC]]>
    <![CDATA[Shubham Pant, MD, MBBS, discusses the management of dermatologic and GI toxicities associated with the RAS(ON) inhibitor daraxonrasib.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[HS-10504 Shows Promising Activity in EGFR C797S–Mutant NSCLC After TKI Resistance]]>
    <![CDATA[Phase 1 data show HS-10504 yields encouraging responses and manageable safety in EGFR C797S–mutant NSCLC post TKI therapy.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer Congress]]>
    <![CDATA[Experts in a range of breast cancer subtypes highlight research data being presented at the 2026 ESMO Breast Cancer Congress.]]>
    onclive · 2mo ago↗ source
  • Viridian data lift prospects for thyroid eye disease drug
    <figure><div><img src="https://imgproxy.divecdn.com/egbyTu8esim-VjYj5FTvMQUlBrndW-s35OSn02s-EoY/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMzk4NTE5MTYzLmpwZ…
    BioPharma Dive · 2mo ago↗ source
  • <![CDATA[The Type of Fat—Not the Amount—Fuels Pancreatic Cancer]]>
    <![CDATA[Research from Yale Cancer Center showed that the type of fat consumed may matter more than amount in pancreatic cancer.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Iopofosine I 131 Follow-Up Data Show Strong Efficacy in Waldenström Macroglobulinemia]]>
    <![CDATA[Iopofosine I 131 produced strong responses in Waldenström macroglobulinemia, according to 12-month folllow-up data from CLOVER WaM requested by the FDA.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr McGregor on Key End Points of the STRIKE Trial of Tivozanib Plus Pembrolizumab in RCC ]]>
    <![CDATA[Bradley McGregor, MD, discusses the end points that will be evaluated in the phase 3 STRIKE trial of adjuvant tivozanib plus pembrolizumab in high-risk RCC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Kuykendall on the Evolving JAK Inhibitor and Transplant Considerations in Myelofibrosis]]>
    <![CDATA[Andrew Kuykendall, MD, explains considerations for JAK inhibitor sequencing and the use of transplant in myelofibrosis.]]>
    onclive · 2mo ago↗ source
  • Vertex earnings get muted investor response
    <p>While overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug Journavx missed analyst estimates by double-digit percentages.</p>
    BioPharma Dive · 2mo ago↗ source
  • Cytokinetics heart drug scores in closely watched trial
    <figure><div><img src="https://imgproxy.divecdn.com/O5l3Ak2w-ITPZwAy2_UP-yuYAxNqpRx2E-yOxBQdi8M/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy05MzA1MTIzNTAuanBn.…
    BioPharma Dive · 2mo ago↗ source
  • <![CDATA[New Endometrial Targets Beyond HER2]]>
    <![CDATA[Interest in endometrial cancer extends well beyond HER2, and the faculty review a growing pipeline of antibody drug conjugates directed at additional targets. Discussion includes why TROPE…
    onclive · 2mo ago↗ source
  • <![CDATA[Coordinating Care in Multiple Myeloma Across Practice Settings ]]>
    <![CDATA[]]>
    onclive · 2mo ago↗ source